-
HEMATOLOGY: Clinical features and neurological outcomes of pediatric immune-mediated thrombotic thrombocytopenic purpura: a report from a large pediatric hematology center
Time of Update: 2022-09-30
Therefore, data on clinical features, comorbidities, treatment response, and long-term outcomes in immunomediated pediatric patients with TTP are limited.
Therefore, data on clinical features, comorbidities, treatment response, and long-term outcomes in immunomediated pediatric patients with TTP are limited.
-
【Am J Hematol Review】First-line treatment of chronic lymphocytic leukemia
Time of Update: 2022-09-30
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, with patients aged 65 to 74 years with a median age of 70 years, so physical fitness may range from very fit to unfit with comorbi
-
Blood Cancer J: The value of the MASS staging system in the prognosis of the new diagnosis of multiple myeloma
Time of Update: 2022-09-30
In order to further test the prognostic value of the MASS staging system in newly diagnosed MM patients in China, Professor Dai Yun and Professor Jin Fengyan of the First Hospital of Jilin University led the analysis of clinical retrospective data of MM patients in 7 centers in China from November 27, 2009 to November 20, 2019, and the results of the study were published in the Blood Cancer Journal.
-
【September 26 (Monday) 19:00 Starlight】The hormone session is about to start!
Time of Update: 2022-09-30
In recent years, the research and application of CAR-T cell therapy has been in full swing around the world, and has shown excellent therapeutic effects in a variety of malignant blood diseases, making the clinical cure of malignant blood diseases possible, and rekindling the hope for countless patients and families.
-
BJH: allogeneic hematopoietic cell transplantation in patients with relapsed/refractory anaplastic large-cell lymphoma
Time of Update: 2022-09-30
Non-recurrence mortality (NRM), disease modeled recurrence/progression (REL), progression-free survival (PFS), and overall survival (OS) using the Cox proportional risk model.
Non-recurrence mortality (NRM), disease modeled recurrence/progression (REL), progression-free survival (PFS), and overall survival (OS) using the Cox proportional risk model.
-
【BLOOD】Outcome after failure of CD19 CART for aggressive B-cell lymphoma from the French DESCAR-T registry study
Time of Update: 2022-09-30
4%) developed disease progression/relapse after CD19 CAR T cell therapy and were the target population for this analysis: 136 patients developed disease progression/relapse after axi-cel treatment (median follow-up time 9.
0 months) and 102 patients developed disease progression/recurrence after tisa-cel treatment (median follow-up time 7.
-
Br J Haematol: Survival prediction optimization for acute myeloid leukemia based on T cell function-related genes and plasma proteins
Time of Update: 2022-09-30
Overall, the study used data on gene expression related to T-cell function to develop a model that can accurately predict the survival of AML patients.
Overall, the study used data on gene expression related to T-cell function to develop a model that can accurately predict the survival of AML patients.
-
Hematopoietic stem cells are artificially manufactured or can meet the needs of hematopoietic stem cell donation from blood diseases
Time of Update: 2022-09-30
The innovation of this study is that the research team developed a microfluidic culture system to simulate the heart beat and blood circulation of the original embryo, and verified the hypothesis that circulatory flow and shear stress promote the blood development of the embryo by the manufactured orbital vibration system.
-
To see is to believe? A case of normal erythrocyte sedimentation results lead to thinking!
Time of Update: 2022-09-30
The cause of the abnormal sample result is found, but why does the erythrocyte evaporation of the specimen not accelerate after dilution?It is reasonable to say that the viscosity of plasma decreases after dilution, at which time the red blood cells are subjected to reduced resistance and therefore accelerate the sinking.
-
Contrast Media Mol Imaging: An analysis of the correlation between post-traumatic growth levels and social support in caregivers of children with acute leukemia
Time of Update: 2022-09-30
But there is currently little research on how self-efficacy plays a role in the relationship between social support and disease-perceived benefits for caregivers in hospitalized patients with acute leukemia.
-
[Br J Haematol] Disease status of follicular lymphoma at 24 months affects mortality
Time of Update: 2022-09-30
Although life expectancy in patients with follicular lymphoma (FL) has improved significantly over the past 20 years, about 20% of patients develop disease progression (POD24) within 24 months of first-line therapy, and this early progression has been shown to be an independent risk factor for low survival.
-
Phase I study results of novel humanized BCMA CAR T cells C-CAR088 in the treatment of RRMM
Time of Update: 2022-09-30
CAR T cell therapy is an important breakthrough in hematologic tumors, with BCMA CAR T cell therapy achieving an overall remission rate (ORR) of 85. 2% and a complete remission (CR) rate of 47. 0% in
-
Cell Reports: Lu Xinjiang's team reveals the mechanism by which Mestrn regulates the mobilization of hematopoietic stem progenitor cells in a hypoxic environment
Time of Update: 2022-09-30
On September 20, 2022, the Lu Xinjiang Research Group of the School of Basic Medicine of Zhejiang University published a research paper "Meteorin links the bone marrow hypoxic state to hematopoietic stem/progenitor cell mobilization" online in the journal Cell Reports.
-
Blood: Outcomes in patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR-T cell therapy
Time of Update: 2022-09-30
The median time to failure of CAR T cell therapy was 2.
The median time to failure of CAR T cell therapy was 2.
The median time to failure of CAR T cell therapy was 2.
-
Parotid mixed tumor - CT case picture diagnostic analysis
Time of Update: 2022-09-30
com such as parotid mixed tumors undergo malignancy, the tumor often grows rapidly suddenly, and can be fixed by adhesion with surrounding tissue.
com such as parotid mixed tumors undergo malignancy, the tumor often grows rapidly suddenly, and can be fixed by adhesion with surrounding tissue.
-
Blood: Does prophylactic use of tranexamic acid reduce the risk of bleeding in patients with hematologic malignancies?
Time of Update: 2022-09-30
Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial.
Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial.
Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial.
-
The FDA approves Beti-Cel gene therapy for pediatric and adult transfusion-dependent β-thalassemia
Time of Update: 2022-09-29
Resources: The FDA approves the betibeglogene autotemcel for pediatric and adult patients β-thalassemia and requiring regular infusions of red blood cells.
Resources: The FDA approves the betibeglogene autotemcel for pediatric and adult patients β-thalassemia and requiring regular infusions of red blood cells.
-
The FDA accepts applications for a new drug for Thermolotinib for the treatment of anemia in myelofibrosis
Time of Update: 2022-09-29
Based on the results of the Phase 3 MOMENTUM trial, the FDA has accepted a new drug application for momelotinib in patients with myelofibrosis.
Acceptance is based on the results of the Phase 3 MOMENTUM trial (NCT04173494), which evaluated the drug compared to danazole in a group of symptomatic patients previously treated with JAK inhibitors.
-
EU approves bispecific antibody Tecvayli (teclistamab) for the treatment of adults with relapsed/refractory multiple myeloma (RRMM)
Time of Update: 2022-09-24
Janssen announced today that the European Commission (EC) has approved the conditional marketing of Tecvayli (teclistamab), a bispecific antibody targeting B cell maturation antigen (BCMA), for the treatment of adults with relapsed/refractory multiple myeloma (RRMM).
-
FDA approves ibrutinib for children with chronic GVHD
Time of Update: 2022-09-24
ly/3cgRdJ8 Based on the results of the Phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for patients with chronic graft-versus-host disease in children .
ly/3cgRdJ8 Based on the results of the Phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for patients with chronic graft-versus-host disease in children .
